Better Cannabis Research Starts With More Inclusive Trials

Before a cannabis clinical trial can measure pain relief, sleep quality, or side effects, someone must agree to participate. That decision can involve much more than interest in a potential treatment. A patient may worry about judgment from family, uncomfortable conversations with a physician, or who will see information about their cannabis use.

A new perspective published in the Journal of Cannabis Research examines how these concerns can affect recruitment among underrepresented populations.¹ Authors Raymond Palidora and colleagues argue that cannabis stigma intersects with familiar research barriers, including transportation difficulties, work commitments, and mistrust of healthcare institutions.

The implications extend beyond filling enrollment targets. Recruitment helps determine whose experiences become medical evidence. Making trials more accessible could improve the usefulness of cannabis research while giving more patients a meaningful opportunity to participate.

Why Cannabis Trial Recruitment Matters for Evidence Quality

Clinical trials answer questions about the people researchers actually study. When participants differ substantially from the patients who may eventually receive a treatment, applying the findings becomes more difficult.

That does not mean every trial must mirror an entire population. Eligibility depends on the condition, intervention, and scientific question. However, avoidable exclusion can leave important uncertainties about treatment experiences, practical barriers, and whether an intervention fits different care settings.

Imagine a study that requires repeated weekday appointments at a distant hospital. It may preferentially enroll people with flexible jobs, reliable transportation, and available childcare. Even a carefully controlled experiment could then provide a limited picture of how manageable that treatment would be outside the research center.

MyCannabis has previously examined the structural barriers slowing cannabis research. The new perspective adds another dimension: obtaining research approval and standardized products does not guarantee that the people needed to answer a clinical question can comfortably enroll.

How Cannabis Stigma Creates Barriers Before Enrollment

The authors describe stigma operating across several levels. Some patients anticipate disapproval from relatives or community members. Others expect dismissive treatment from clinicians. Internalized stigma can also make someone uncomfortable acknowledging their own cannabis use, even when they are seeking symptom relief.

These pressures can influence participation before a research coordinator ever makes contact. If patients avoid discussing cannabis, clinicians may never identify their interest. If clinicians are uncomfortable with cannabis research, eligible patients may never hear about an available trial.

This makes referral practices an important part of recruitment. A beautifully written invitation cannot help someone who never receives it.

Legal Permission Does Not Automatically Create Trust

Social attitudes do not necessarily change at the same pace as legislation. MyCannabis coverage of cannabis laws and scientific terminology explains why legal classifications, biological effects, and social judgments should be considered separately.

The perspective similarly emphasizes that patients may remain concerned about disclosure despite changing policies. Some concerns involve perceived consequences; others may reflect real circumstances requiring careful, locally appropriate guidance. Researchers cannot resolve every concern with a general statement that participation is confidential.

Trust depends on explaining what confidentiality means in that particular study, including its limits.

What the Paper Recommends for More Inclusive Cannabis Trials

The paper proposes a framework drawing on cannabis literature and lessons from broader clinical research, particularly oncology. The following examples summarize barriers and corresponding approaches presented in its framework.

These are proposed approaches, not results from a new trial demonstrating that a specific recruitment package works. Their value is that they identify practical changes researchers can test rather than treating low participation as a fixed feature of a community.

Patient Privacy Should Be Part of Trial Design

One useful implication is that privacy should influence how a study operates from its first contact with a potential participant.

Consider an invitation mentioning cannabis in a voicemail heard by other household members. Or an appointment reminder appearing on a shared device. Neither example requires malicious behavior to create discomfort. The communication method itself may discourage someone from continuing.

As a practical extension of the framework, research teams could ask participants how they prefer to be contacted and what information can safely appear in messages. Consent discussions could also address concrete questions:

• Who can access identifiable information about my participation?
• How will the research team contact me?
• What information might enter my medical record?
• What are the limits of confidentiality?

The answers will differ between studies. Providing specific answers is more useful than offering broad reassurance that leaves participants to imagine the details.

Community Partnerships Can Improve Research Questions

Trusted community organizations can help researchers communicate, but their contribution could begin earlier. Involving patients and community representatives while designing a study may reveal obstacles that recruitment materials alone cannot fix.

For example, a study team might assume that a longer appointment reduces inconvenience by combining several assessments. Patients balancing caregiving responsibilities may instead find shorter visits easier to manage. Researchers cannot reliably resolve that tradeoff without asking.

Community input could also improve the relevance of outcomes. A numerical symptom score may be important, while patients may additionally care about functioning at work, managing household responsibilities, or avoiding unwanted impairment.

These are opportunities to strengthen study design. They do not require assuming that members of a racial, ethnic, or cultural group share identical preferences. Good engagement creates space for differences within communities as well as between them.

Measure Where Cannabis Trial Participation Breaks Down

Another implication is that researchers should examine the entire enrollment pathway. A final demographic breakdown shows who enrolled, but reveals less about why others did not.

Teams could track how many people were identified as potentially eligible, contacted, screened, invited, enrolled, and retained. Where appropriate and voluntarily provided, reasons for declining could distinguish scheduling problems from privacy concerns or lack of interest.

That distinction matters because different problems require different responses. Staff education will not solve an unaffordable journey. Transportation assistance will not resolve uncertainty about who can access sensitive information.

There is a broader movement toward making participation more visible. In September 2026, NIH announced more detailed clinical research enrollment data by research category. Such reporting supports scrutiny of representation, although aggregate statistics cannot explain every local recruitment barrier.

What the Evidence Establishes and What Still Needs Testing

The paper is a perspective, not a randomized recruitment experiment or a systematic review establishing the size of every barrier. Its authors acknowledge that direct evidence connecting cannabis stigma with trial enrollment remains limited. Much of the discussion draws on related research settings, and its predominantly U.S. context limits straightforward application elsewhere.

Nevertheless, the concern fits a broader evidence base. A separate 2026 synthesis of medical cannabis patient experiences, covering 45 qualitative studies, identified recurring themes involving education gaps, stigma, social consequences, and difficult access pathways. That supports taking patient concerns seriously, while leaving open which interventions best improve recruitment.

The next step is to compare approaches prospectively. Researchers could evaluate whether privacy-focused invitations, community partnerships, or flexible follow-up improve participation and retention. They should also assess whether participants understand the research and feel free to decline.

Better Cannabis Research Starts With a Better Invitation

Inclusive recruitment should preserve scientific standards and voluntary choice. Its purpose is to remove avoidable obstacles so eligible patients can make an informed decision.

That offers a practical route forward. Cannabis trials can become more accessible through clearer communication, thoughtful scheduling, better referral practices, and transparent handling of sensitive information. Each change is measurable.

More representative enrollment will not guarantee that a cannabis treatment succeeds. It can help researchers establish more confidently where benefits exist, where risks emerge, and whom the findings actually serve. That is progress patients and clinicians can use.

References:

¹ Palidora, R., Levy, S., Ashare, R., Meghani, S., & Worster, B. (2026). Overcoming cannabis-related stigma and barriers in clinical trial recruitment among underrepresented populations. Journal of Cannabis Research. Advance online publication. https://doi.org/10.1186/s42238-026-00525-6